The HealthShares Respiratory/Pulmonary ETF (Ticker: HHR) seeks to replicate as closely as possible, before expenses, the total return performance of the HealthShares Respiratory/Pulmonary Index. The index is comprised of companies engaged in the research, development, and/or commercialization of therapeutic agents treating various respiratory and/or pulmonary diseases including asthma, chronic obstructive pulmonary disease, emphysema, tuberculosis and pulmonary arterial hypertension. Companies must have a minimum market capitalization greater than $100 million and less than $15 billion for at least two of the three proceeding quarters. Stocks are equally weighted when the fund is formed and then float with the market thereafter. When the weight of an individual stock reaches 15% of the index value it is adjusted down to 10%, and when a stocks falls to 2.5% it is adjusted up to 5%. S&P is the administrator of HealthShares indexes.